Obligation technology is advancing $ 50 million to the Commercial Deployment Deployment Safety syringe

Second commercial delivery in progress as part of a multi -year contract with the main American health partner

Strategic manufacturing upgrades stimulate scalability, efficiency and increase the ability to support production growth

New York, June 18, 2025 (Globe Newswire) – Sharps Technology, Inc. (Nasdaq: “STSSW” and “STSSW”) (“Sharps”), an innovative medical devices and pharmaceutical packaging now offering an update of the best explanation of intelligent safety in the health sector, $ 50 million Sologard sales contract, as well as a series of advanced manufacturing upgrades.

Sharps launched the second expedition of its first commercial order of Sologard syringes by virtue of a multi -year supply agreement with an American leader in rinse IV solutions. In preparation for the increase in production throughout the year, Sologard Manufacturing will be supported by newly installed molding and automation systems – investments which allow sharp objects to meet the demand provided for the second half of 2025 as part of the sales agreement.

As part of a progressive manufacturing upgrading strategy, Sharps implements the following initiatives:

• Preparation and realization of the second expedition under the multi -year agreement, continuing to meet customer demand
• Deployment of new generation injection molding systems to extend manufacturing capacity and rationalize white room operations
• Installation of new machines offering more than 10x energy efficiency compared to previous systems, reducing the costs and progressing of sustainable production
• Upgrades to installations to white room environments and control systems, improving product quality and regulatory compliance
• Integration of new auxiliary systems to increase flow and optimize molding and assembly workflows

Sharps currently performs a $ 400,000 Purchase order, announced on June 4, 2025, as part of a larger five -year agreement to provide up to 500 million Sologard syringes, marking the company’s transition into commercial operations generating income. The contract includes personalized 10 ml intelligent safety syringes of 10 ml – FDA devices and approved by WHO which includes an ultra -basic waste design, standard Luer locking compatibility and reusing prevention technology.

Robert Hayes, CEO of Sharps Technology, commented: “The realization of this second expedition marks an important step while we are going to commercial execution under the $ 50 million Sologard agreement. In recent months, we have made strategic investments in advanced molding systems, automation and indoor infrastructure. These are transformational upgrades that increase capacity while improving energy efficiency, consistency and our overall cost structure. These improvements are at the heart of our long -term strategy, allowing sharp objects to carry out major contracts, failure of recurring income and to position the company as a manufacturing partner focused on the health care industry. »»

About sharp objects technology:
Sharps technology is an innovative company of medical devices and pharmaceutical packaging offering patented syringe products and best-security in the best category in the health care industry. The company’s product ranges focus on the supply of ultra -low waste capabilities, which incorporate syringe technologies that use passive and active safety functionalities. Retling objects also offers products designed with specialized copolymer technology to support the preflable syringe market segment. The company has a manufacturing plant in Hungary. For more information, please visit www.sharpstechnology.com.

Prospective declarations:
This press release contains “prospective declarations”. Prospective declarations reflect our current point of view on future events. When used in this press release, the words “anticipate”, “believe”, “believe”, “wait”, “future”, “consider”, “plan”, “ready” or the negative of these terms and similar expressions, with regard to us or our management, identify prospective declarations. These statements include, but without limiting themselves, the statements contained in this press release concerning our commercial strategy, our future operating results and liquidity and the prospects for capital resources. Prospective declarations are based on our current expectations and hypotheses concerning our business, our economy and other future conditions. Since prospective declarations concern the future, they are subject to uncertainties, risks and changes in circumstances that are difficult to foresee. Our real results may differ materially from those envisaged by prospective declarations. These are neither historical de facto statements nor guarantees of future performance insurance. We therefore warn you to count on one of these prospective declarations. Important factors that could ensure that real results differ significantly from those of prospective statements include, without limitation, our capacity to raise capital to finance continuous operations; Our ability to protect our intellectual property rights; the impact of any infringement actions or other disputes that have been submitted to us; competition from other suppliers and products; our ability to develop and market products and services; changes in government regulations; our ability to carry out capital lifting transactions; and other factors relating to our industry, our operations and our operations results. Real results may differ considerably from those that have been planned, raw, estimated, expected, doomed or planned. The factors or events that could defer our real results can emerge from time to time, and it is not possible for us to predict them all. We cannot guarantee future results, activity levels, performance or achievements. The company assumes no obligation to update prospective declarations in order to reflect any event or circumstance which may occur after the date of this version.

Investor contact:
Holdworth Partners
Adam Holdsworth
Telephone: 917-497-9287
E-mail: Ir@sharpstechnology.com